![ASCO GI 2023 Biomarker Study of The Phase III PARADIGM Trial: Negative Hyperselection of Patients With RAS WT mCRC for Panitumumab | VuMedi ASCO GI 2023 Biomarker Study of The Phase III PARADIGM Trial: Negative Hyperselection of Patients With RAS WT mCRC for Panitumumab | VuMedi](http://media.vumedi.com/thumbs/video/2023/1/8eadb197-92b8-4812-989b-0d6f9d0f979f.300x170_q85_crop-smart_upscale.jpg)
ASCO GI 2023 Biomarker Study of The Phase III PARADIGM Trial: Negative Hyperselection of Patients With RAS WT mCRC for Panitumumab | VuMedi
![Seyda Gunduz on X: "#PARADIGM trial First-line Panitumab is superior to bevacizumab in the left-sided RAS wild metastatic colon cancer #ASCO22 https://t.co/6XLAWIK1c2" / X Seyda Gunduz on X: "#PARADIGM trial First-line Panitumab is superior to bevacizumab in the left-sided RAS wild metastatic colon cancer #ASCO22 https://t.co/6XLAWIK1c2" / X](https://pbs.twimg.com/media/FUgoU1uXoAUm2ie.jpg)
Seyda Gunduz on X: "#PARADIGM trial First-line Panitumab is superior to bevacizumab in the left-sided RAS wild metastatic colon cancer #ASCO22 https://t.co/6XLAWIK1c2" / X
![Panitumumab Combined With FOLFOX Emerges As the New First-Line PARADIGM for Left-Sided RAS Wild-Type Metastatic Colorectal Cancer | ASCO Daily News Panitumumab Combined With FOLFOX Emerges As the New First-Line PARADIGM for Left-Sided RAS Wild-Type Metastatic Colorectal Cancer | ASCO Daily News](https://dailynews.ascopubs.org/do/10.1200/ADN.22.201008/full/dn22_lba1_fig-1654472993471.jpg)
Panitumumab Combined With FOLFOX Emerges As the New First-Line PARADIGM for Left-Sided RAS Wild-Type Metastatic Colorectal Cancer | ASCO Daily News
![Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline - Irene S. Yu, Francine Aubin, Rachel Goodwin, Jonathan M. Loree, Cheryl Mather, Brandon S. Sheffield, Stephanie Snow, Sharlene Gill, Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline - Irene S. Yu, Francine Aubin, Rachel Goodwin, Jonathan M. Loree, Cheryl Mather, Brandon S. Sheffield, Stephanie Snow, Sharlene Gill,](https://journals.sagepub.com/cms/10.1177/17588359221111705/asset/images/large/10.1177_17588359221111705-fig1.jpeg)
Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline - Irene S. Yu, Francine Aubin, Rachel Goodwin, Jonathan M. Loree, Cheryl Mather, Brandon S. Sheffield, Stephanie Snow, Sharlene Gill,
![Panitumumab Combined With FOLFOX Emerges As the New First-Line PARADIGM for Left-Sided RAS Wild-Type Metastatic Colorectal Cancer Panitumumab Combined With FOLFOX Emerges As the New First-Line PARADIGM for Left-Sided RAS Wild-Type Metastatic Colorectal Cancer](https://dailynews.ascopubs.org/do/10.1200/ADN.22.201008/full/dn22_lba1_fig_thumbnail-1654472993490.jpg)
Panitumumab Combined With FOLFOX Emerges As the New First-Line PARADIGM for Left-Sided RAS Wild-Type Metastatic Colorectal Cancer
![Personalized Care in Colorectal Cancer: Tailoring Treatment and Healthcare Delivery - Personalized Medicine in Oncology Personalized Care in Colorectal Cancer: Tailoring Treatment and Healthcare Delivery - Personalized Medicine in Oncology](https://www.personalizedmedonc.com/wp-content/uploads/2017/04/FigureCC_PMOMarch2017.png)
Personalized Care in Colorectal Cancer: Tailoring Treatment and Healthcare Delivery - Personalized Medicine in Oncology
![Panitumumab beats bevacizumab in RAS wildtype left-sided metastatic colorectal cancer - Medical Conferences Panitumumab beats bevacizumab in RAS wildtype left-sided metastatic colorectal cancer - Medical Conferences](https://conferences.medicom-publishers.com/wp-content/uploads/2022/08/ASCO2022_Fig-Overall-survival-panitumumab.png)
Panitumumab beats bevacizumab in RAS wildtype left-sided metastatic colorectal cancer - Medical Conferences
![Cancers | Free Full-Text | A Review of Translational Research for Targeted Therapy for Metastatic Colorectal Cancer Cancers | Free Full-Text | A Review of Translational Research for Targeted Therapy for Metastatic Colorectal Cancer](https://www.mdpi.com/cancers/cancers-15-01395/article_deploy/html/images/cancers-15-01395-g001-550.jpg)
Cancers | Free Full-Text | A Review of Translational Research for Targeted Therapy for Metastatic Colorectal Cancer
![Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy‐naïve Patients With RAS (KRAS/NRAS) Wild‐type, Metastatic Colorectal Cancer | Semantic Scholar Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy‐naïve Patients With RAS (KRAS/NRAS) Wild‐type, Metastatic Colorectal Cancer | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/7d31b6af53d12b2f1ceaf1b7899874e6d602d624/3-Figure1-1.png)
Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy‐naïve Patients With RAS (KRAS/NRAS) Wild‐type, Metastatic Colorectal Cancer | Semantic Scholar
![Cancers | Free Full-Text | Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)—Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC) Cancers | Free Full-Text | Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)—Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC)](https://www.mdpi.com/cancers/cancers-14-03078/article_deploy/html/images/cancers-14-03078-g002.png)
Cancers | Free Full-Text | Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)—Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC)
![Cancers | Free Full-Text | ctDNA and Adjuvant Therapy for Colorectal Cancer: Time to Re-Invent Our Treatment Paradigm Cancers | Free Full-Text | ctDNA and Adjuvant Therapy for Colorectal Cancer: Time to Re-Invent Our Treatment Paradigm](https://www.mdpi.com/cancers/cancers-13-00346/article_deploy/html/images/cancers-13-00346-g001.png)
Cancers | Free Full-Text | ctDNA and Adjuvant Therapy for Colorectal Cancer: Time to Re-Invent Our Treatment Paradigm
![Comprehensive review of targeted therapy for colorectal cancer | Signal Transduction and Targeted Therapy Comprehensive review of targeted therapy for colorectal cancer | Signal Transduction and Targeted Therapy](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41392-020-0116-z/MediaObjects/41392_2020_116_Fig1_HTML.png)